Free Trial

Intra-Cellular Therapies (ITCI) News Today

Intra-Cellular Therapies logo
$131.87 0.00 (0.00%)
As of 04/2/2025
Intra-Cellular Therapies, Inc. stock logo
Headlands Technologies LLC Buys 2,883 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Headlands Technologies LLC raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,065 shares of the biopharmaceutical c
Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst
Intra-Cellular Therapies, Inc. stock logo
Axiom Investors LLC DE Has $5.02 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Axiom Investors LLC DE lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,101 shares of the biopharmac
Intra-Cellular Therapies, Inc. stock logo
Schroder Investment Management Group Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Schroder Investment Management Group reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 19.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 743,230 shares of the biopharmaceutical company's stock after selling 180,
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year High - Time to Buy?
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 52-Week High - Here's What Happened
Intra-Cellular Therapies, Inc. stock logo
Clearbridge Investments LLC Sells 43,345 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Clearbridge Investments LLC trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,686,384 shares of the biopharmac
Intra-Cellular Therapies, Inc. stock logo
DnB Asset Management AS Trims Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
DnB Asset Management AS lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,569 shares of the biopharmaceutical com
Intra-Cellular Therapies, Inc. stock logo
Norges Bank Makes New $268.35 Million Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Norges Bank acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,212,964 shares of the biopharmaceutical company's stock, valued at approxi
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Decreased by JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,126,092 shares of the biopharmaceutical company's stock afte
Intra-Cellular Therapies, Inc. stock logo
Vanguard Group Inc. Grows Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Vanguard Group Inc. raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,721,360 shares of the biopharmaceutic
Intra-Cellular Therapies, Inc. stock logo
American Century Companies Inc. Raises Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
American Century Companies Inc. increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 314,362 shares of
Intra-Cellular Therapies, Inc. stock logo
Pictet Asset Management Holding SA Has $128.66 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Pictet Asset Management Holding SA reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owne
Intra-Cellular Therapies, Inc. stock logo
KLP Kapitalforvaltning AS Makes New $1.71 Million Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
KLP Kapitalforvaltning AS bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 20,500 shares of the biopharmaceutical company'
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of "Hold" by Analysts
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, five have g
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. stock logo
Sei Investments Co. Acquires 14,379 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Sei Investments Co. boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,806 shares of the biopharmac
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com
StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday. They set a "hold" rating on the stock.
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Teacher Retirement System of Texas
Teacher Retirement System of Texas boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,159 shares of the biopharmaceutical company's stock after purchasing an a
Intra-Cellular Therapies, Inc. stock logo
EFG Asset Management North America Corp. Purchases 37,061 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
EFG Asset Management North America Corp. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 99.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,190 shares of the biopharma
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month High - Time to Buy?
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High - Here's Why
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Emerald Advisers LLC
Emerald Advisers LLC reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,066 shares of th
Intra-Cellular Therapies, Inc. stock logo
Simplify Asset Management Inc. Has $1.69 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Simplify Asset Management Inc. lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 34.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,268 shares of
Intra-Cellular Therapies, Inc. stock logo
Fox Run Management L.L.C. Purchases Shares of 16,667 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Fox Run Management L.L.C. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,667 shares of the biopharmaceutical company's stock, valued at approxim
Intra-Cellular Therapies, Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Sells 7,488 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 43.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,61
Intra-Cellular Therapies, Inc. stock logo
Privium Fund Management B.V. Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Privium Fund Management B.V. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,154 shares of the biopharmaceutical company's stock af
Intra-Cellular Therapies, Inc. stock logo
Proficio Capital Partners LLC Invests $1.59 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Proficio Capital Partners LLC bought a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,043 shares of the biopharmaceutical company's
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Thursday. They issued a "hold" rating on the stock.
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High - Time to Buy?
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 52-Week High - Here's Why
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 9.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,639 shares of the biopharmaceutical company's stock
Intra-Cellular Therapies, Inc. stock logo
AlphaQuest LLC Has $333,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
AlphaQuest LLC increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 49,687.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,983 shares of the biopharmaceutical company
Intra-Cellular Therapies, Inc. stock logo
US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
US Bancorp DE trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 54.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,621 shares of the biopharmaceutical company's stock after selling 4
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 1-Year High - What's Next?
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High - Here's What Happened
Intra-Cellular Therapies, Inc. stock logo
Jones Financial Companies Lllp Acquires 2,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Jones Financial Companies Lllp increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 71.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,590 shares of the biopharmaceutical
Intra-Cellular Therapies, Inc. stock logo
Raymond James Financial Inc. Invests $76.45 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Raymond James Financial Inc. acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 915,361 shares of the biopharmaceutical company's stock, valued
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 359,045 shares
Intra-Cellular Therapies, Inc. stock logo
Lisanti Capital Growth LLC Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Lisanti Capital Growth LLC boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 24.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,600 shares of the biopharmaceutical compan
Intra-Cellular Therapies, Inc. stock logo
Candriam S.C.A. Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Candriam S.C.A. raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 214,320 shares of the biopharmaceutical company's stock after pu
Intra-Cellular Therapies, Inc. stock logo
Inceptionr LLC Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Inceptionr LLC acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,375 shares of the biopharmaceutical co
Intra-Cellular Therapies, Inc. stock logo
Proficio Capital Partners LLC Purchases Shares of 19,043 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Proficio Capital Partners LLC purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 19,043 shares of the biopharmaceutical company's stock, valued at
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Aigen Investment Management LP
Aigen Investment Management LP grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 35.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,153 shares of the biopharmaceutical company's st
Intra-Cellular Therapies, Inc. stock logo
Cookson Peirce & Co. Inc. Invests $975,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Cookson Peirce & Co. Inc. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 11,670 shares of the biopharmaceutical company's stock, valued at appro
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of "Hold" from Brokerages
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have received an average rating of "Hold" from the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, five have issu
Intra-Cellular Therapies, Inc. stock logo
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 44.4% in February
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 2,310,000 shares, an increase of 44.4% from the January 31st total of 1,600,000 shares. Based on an average trading volume of 2,460,000 shares, the short-interest ratio is presently 0.9 days.
Remove Ads
Get Intra-Cellular Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

ITCI Media Mentions By Week

ITCI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ITCI
News Sentiment

1.07

0.60

Average
Medical
News Sentiment

ITCI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ITCI Articles
This Week

21

8

ITCI Articles
Average Week

Remove Ads
Get Intra-Cellular Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ITCI) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners